Despite its relative prevalence in high-grade gliomas such as GMB, EGFRvIII, a constitutively activating mutation with intragenic deletion of exons 2 to 7, is not often found in LGG (Newman et al., 2017; Huang et al., 2018); however, some oncogenic mutations of EGFR, such as A289V, R108K, and G598V, are found in LGG patients. This evidence concerns the gene EGFR and glioma.